Skip to content
DraconiticResearch
Search Sources API
186,625 studies31 sourcesUpdated 56 min ago
Peer-reviewedCC BYFrontiers in oncology

Complete response in unresectable HER2+ cholangiocarcinoma with histotripsy and systemic therapy followed by liver transplantation: a case report.

  • Tiffany M Juarez1
  • Jimmy Ton2
  • Ivan Babin2
  • Chase J Wehrle3
  • Victoria Chuchua2
  • Santosh Kesari4
  • Bin S Teh5
  • Sadhna Dhingra6
  • Ashish Saharia7,8
  • Ashton Connor7,8
  • Sudha Kodali8
  • Kevin Burns2
8 affiliations
  1. 1Leonard Cancer Institute, Providence Mission Hospital, Mission Viejo, CA, United States.
  2. 2Department of Interventional Radiology, Providence Mission Hospital, Mission Viejo, CA, United States.
  3. 3Liver Transplantation & HPB Surgery, Cleveland Clinic Foundation, Cleveland, OH, United States.
  4. 4Department of Neuro-Oncology, Providence Mission Hospital, Mission Viejo, CA, United States.
  5. 5Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, United States.
  6. 6Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, United States.
  7. 7JC Walter Jr Center for Transplantation, Houston Methodist Hospital, Houston, TX, United States.
  8. 8Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, United States.
Read full textPDFDOICite

Abstract

Intrahepatic cholangiocarcinoma carries a poor prognosis making its management challenging. Histotripsy is a non-invasive, non-ionizing, and non-thermal therapy that mechanically disrupts tumors through acoustic cavitation. We present the case of a 59-year-old man with locally advanced, multifocal, stage II intrahepatic cholangiocarcinoma who achieved a complete pathologic response in the explanted liver after treatment with histotripsy and systemic drug therapy consisting of gemcitabine, cisplatin, durvalumab, and trastuzumab deruxtecan. This case highlights the potential role of noninvasive histotripsy as a bridging therapy to transplantation in selected patients with cholangiocarcinoma.

Related

  1. Modified Sullivan-type segment III hepatojejunostomy for radiologically presumed unresectable hilar cholangiocarcinoma: a technical case report
    Journal of surgical case reportsPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  2. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial
    Tanios Bekaii‐Saab, Davide Melisi, Hanneke W. Wilmink +24
    Journal of Clinical OncologyPeer-reviewedLicence not statedFull text10 citedSurgery & anaesthesiaOpenAlex
  3. Case Report: From unresectable to resectable: successful conversion therapy with TACE, HAIC, envafolimab, and olaparib in advanced intrahepatic cholangiocarcinoma
    Chi Ma, Kun Feng, Jun Zhou
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaPMCCrossrefEurope PMC
  4. Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report.
    Yingying Hang, Lu Bai, Hsiquan Hsu +7
    The oncologistPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  5. Inhibition of the ZEB1–BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma
    Ester Gonzalez-Sanchez, Marie Vallette, Lucia Garcia-Collado +15
    Biomedicine and PharmacotherapyPeer-reviewedCC BY-NC 4.0Full textSurgery & anaesthesiaHAL

Cite

BibTeXRIS
BibTeX
@article{juarez2026complete,
  title = {{Complete response in unresectable HER2+ cholangiocarcinoma with histotripsy and systemic therapy followed by liver transplantation: a case report.}},
  author = {Tiffany M Juarez and Jimmy Ton and Ivan Babin and Chase J Wehrle and Victoria Chuchua and Santosh Kesari and Bin S Teh and Sadhna Dhingra and Ashish Saharia and Ashton Connor and Sudha Kodali and Kevin Burns},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1740407},
  url = {https://europepmc.org/article/MED/42908588},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Complete response in unresectable HER2+ cholangiocarcinoma with histotripsy and systemic therapy followed by liver transplantation: a case report.
AU  - Tiffany M Juarez
AU  - Jimmy Ton
AU  - Ivan Babin
AU  - Chase J Wehrle
AU  - Victoria Chuchua
AU  - Santosh Kesari
AU  - Bin S Teh
AU  - Sadhna Dhingra
AU  - Ashish Saharia
AU  - Ashton Connor
AU  - Sudha Kodali
AU  - Kevin Burns
PY  - 2026
DA  - 2026/10/07
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1740407
UR  - https://europepmc.org/article/MED/42908588
AB  - Intrahepatic cholangiocarcinoma carries a poor prognosis making its management challenging. Histotripsy is a non-invasive, non-ionizing, and non-thermal therapy that mechanically disrupts tumors through acoustic cavitation. We present the case of a 59-year-old man with locally advanced, multifocal, stage II intrahepatic cholangiocarcinoma who achieved a complete pathologic response in the explanted liver after treatment with histotripsy and systemic drug therapy consisting of gemcitabine, cisplatin, durvalumab, and trastuzumab deruxtecan. This case highlights the potential role of noninvasive histotripsy as a bridging therapy to transplantation in selected patients with cholangiocarcinoma.
SN  - 2234-943X
ER  -